Pyridines and derivatives
Pigment Orange 43 94.0+%, TCI America™
CAS: 4424-06-0 Molecular Formula: C26H12N4O2 Molecular Weight (g/mol): 412.408 MDL Number: MFCD00071829 InChI Key: DGBWPZSGHAXYGK-UHFFFAOYSA-N Synonym: Vat Orange 7 PubChem CID: 78141 SMILES: C1=CC=C2C(=C1)N=C3N2C(=O)C4=CC=C5C6=C(C=CC3=C46)C(=O)N7C5=NC8=CC=CC=C87
Medchemexpress LLC Eudesmin | 526-06-7 | 1 MG
Eudesmin ((-)-Eudesmin) functions by impairing adipogenic differentiation through the inhibition of the S6K1 signaling pathway. It is noted for its diverse therapeutic properties, which include anti-tumor, anti-inflammatory, and anti-bacterial activities.
- Impairs adipogenic differentiation through inhibition of the S6K1 signaling pathway.
- Exhibits diverse therapeutic properties, including anti-tumor, anti-inflammatory, and anti-bacterial activities.
- Inhibits activation and nuclear translocation of S6K1.
- Reduces S6K1-mediated phosphorylation of H2B at serine 36 (H2BS36p).
- Disturbs adipogenesis in mesenchymal stem cells.
Medchemexpress LLC Eudesmin | 526-06-7 | 5 MG
Eudesmin impairs adipogenic differentiation via inhibition of the S6K1 signaling pathway. It possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.
- Impares adipogenic differentiation via inhibition of the S6K1 signaling pathway.
- Possesses anti-tumor activities.
- Possesses anti-inflammatory activities.
- Possesses anti-bacterial activities.
- Inhibits activation and nuclear translocation of S6K1.
- Reduces S6K1-mediated phosphorylation of H2B at serine 36.
Apexbio Technology LLC Org 27569 868273-06-7 50mg
Org 27569 (CAS 868273-06-7) is an allosteric modulator targeting the cannabinoid CB1 receptor It enhances the binding of the agonist CP55940 to purified CB1 receptors while simultaneously inhibiting receptor functionality In electrically-stimulated mouse vas deferens assays Org 27569 reduced WIN55212-induced contractions exhibiting a pEC50 of 8 24 0 12 and a maximal response (Emax) of approximately 45 4% Binding studies suggest its interaction at a putative allosteric site on CB1 receptors reflected by parameters such as a pKB of 5 67 0 23 and a Log of 1 14 0 17 Org 27569 serves as a tool compound for studying CB1 receptor allosteric modulation
Medchemexpress LLC Brilanestrant | 1365888-06-7 | 99.9% | 100 MG
Brilanestrant is an orally bioavailable selective estrogen receptor degrader (SERD) with an IC50 of 0.7 nM. It is intended for research use only.
- Orally bioavailable selective estrogen receptor degrader
- Potent ER-α binder
- Full transcriptional antagonist with no agonism
- Induces ER-α degradation
- Shows efficacy in MCF-7 breast cancer cell viability assays
- Exhibits low clearance and good oral bioavailability
- Demonstrates tumor-growth inhibition in MCF-7 xenograft models
Medchemexpress LLC Vecabrutinib | 1510829-06-7 | 529.92 | 25 MG
Vecabrutinib (SNS-062) is a potent, noncovalent BTK and ITK inhibitor. It demonstrates high potency with Kd values of 0.3 nM for BTK and 2.2 nM for ITK, and an IC50 of 24 nM for ITK. This compound retains activity against mutated BTK variants and is well-tolerated in vivo.
- Potent noncovalent BTK and ITK inhibitor
- Active against mutated BTK variant
- Six times more potent than PCI-32765 against C481S BTK
- Good oral bioavailability in rat and dog
- Decreases viability of primary CLL cells
Medchemexpress LLC M2n12 | 2376577-06-7 | 98.2% | 1 MG
M2N12 is a potent and highly selective cell division cycle 25C protein phosphatase (Cdc25C) inhibitor. It also shows promising activity against Cdc25A and Cdc25B. M2N12 exhibits anti-tumor activity and is suitable for cancer research.
- Potent and highly selective Cdc25C inhibitor with an IC50 value of 0.09 μM.
- Active against Cdc25A (IC50: 0.53 μM) and Cdc25B (IC50: 1.39 μM).
- Exhibits anti-tumor activity, suitable for cancer research.
- Demonstrates cytotoxic activity against multiple tumor cell lines, including A549, KB, and MCF7.
- Appearance is solid, brown to red.
Medchemexpress LLC M2N12 | 2376577-06-7 | 98.2% | 25 MG
M2N12 is a potent and highly selective Cdc25C protein phosphatase inhibitor with an IC50 of 0.09 μM. It also demonstrates promising activity against Cdc25A and Cdc25B, with IC50 values of 0.53 μM and 1.39 μM, respectively. This compound exhibits anti-tumor activity and is suitable for cancer research.
- Potent and highly selective cell division cycle 25C protein phosphatase (Cdc25C) inhibitor
- IC50 value against Cdc25C is 0.09 μM
- Shows activity against Cdc25A (IC50: 0.53 μM) and Cdc25B (IC50: 1.39 μM)
- Possesses anti-tumor activity
- Suitable for cancer research
- Cytotoxic activity against various tumor cell lines (A-549, MDA-MB-231, KB, KB-VIN, MCF-7) and a normal cell line (HBE)
Medchemexpress LLC M2N12 | 2376577-06-7 | 98.2% | 1 ML
M2N12 is a potent and highly selective inhibitor of cell division cycle 25C protein phosphatase (Cdc25C) with an IC50 value of 0.09 μM. It also shows activity against Cdc25A (IC50 = 0.53 μM) and Cdc25B (IC50 = 1.39 μM). This product exhibits anti-tumor activity and is suitable for cancer research.
- Potent and highly selective inhibitor of Cdc25C.
- Shows activity against Cdc25A and Cdc25B.
- Exhibits anti-tumor activity.
- Suitable for cancer research.
- Exhibits cytotoxic activity against several tumor cell lines.
Medchemexpress LLC Brilanestrant | 1365888-06-7 | 99.9% | 50 MG
Brilanestrant is an orally bioavailable selective estrogen receptor degrader (SERD) with an IC50 of 0.7 nM. It acts as a potent ER-α binder (IC50=6.1 nM) and a full transcriptional antagonist with no agonism (3x ERE, IC50=2 nM). It demonstrates good potency and efficacy in ER-α degradation (EC50=0.7 nM) and MCF-7 breast cancer cell viability (IC50=2.5 nM) assays.
- Orally bioavailable selective estrogen receptor degrader (SERD)
- Potent ER-α binder (IC50=6.1 nM)
- Full transcriptional antagonist with no agonism
- Induces a distinct ERα conformation
- Does not show tamoxifen-like ER agonism in MCF7 cells
- Low clearance and good bioavailability (40%-60%)
- Substantial tumor-growth inhibition in tamoxifen-sensitive MCF-7 xenograft model
- Displays dose-dependent efficacy in MCF7 xenograft model
Medchemexpress LLC Brilanestrant | 1365888-06-7 | 99.9% | 25 MG
Brilanestrant is an orally bioavailable selective estrogen receptor degrader (SERD) with an IC₅₀ of 0.7 nM. It demonstrates potency and efficacy in ER-α degradation and MCF-7 breast cancer cell viability assays, acting as a full transcriptional antagonist without agonism. It induces a distinct ERα conformation and does not exhibit tamoxifen-like ER agonism in MCF7 cells.
- Potent ER-α binder.
- Full transcriptional antagonist with no agonism.
- Effective in ER-α degradation and MCF-7 breast cancer cell viability assays.
- Induces a distinct ERα conformation and lacks tamoxifen-like ER agonism.
- Exhibits low clearance and good bioavailability across species.
- Demonstrates substantial tumor-growth inhibition in tamoxifen-sensitive MCF-7 xenograft models.
Medchemexpress LLC Vecabrutinib | 1510829-06-7 | 99.8% | 529.92 | 1 ML
Vecabrutinib | 1510829-06-7 | 99.8% | 529.92 | 1 ML
Medchemexpress LLC Naluzotan | 740873-06-7 | 98.05% | 450.64 | 1 MG
Naluzotan is a novel, potent, and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of approximately 20 nM and 5.1 nM, respectively. It is used for the treatment of anxiety and depression. It also acts as a weak hERG K+ channel blocker, with an IC50 of 3800 nM.
- Novel, potent, and selective amidosulfonamide 5-HT1A agonist
- Used for the treatment of anxiety and depression
- Acts as a weak hERG K+ channel blocker
- Exhibits full agonism in in vitro functional assays
- Shows significant affinity for the guinea pig sigma receptor
- Does not inhibit major cytochrome P450 isoforms
- Demonstrates significant brain penetration
Medchemexpress LLC M2N12 | 2376577-06-7 | 98.2% | 393.83 | 5 MG
M2N12 is a potent and highly selective Cdc25C protein phosphatase inhibitor. It demonstrates activity against Cdc25A and Cdc25B, and possesses anti-tumor properties, making it suitable for cancer research.
- Potent and highly selective Cdc25C inhibitor (IC50 = 0.09 μM)
- Active against Cdc25A (IC50 = 0.53 μM) and Cdc25B (IC50 = 1.39 μM)
- Exhibits anti-tumor activity
- Suitable for cancer research applications
- Appears as a brown to red solid
- Soluble in DMSO (11.11 mg/mL)
- Effective against multiple tumor cell lines including A549, KB, and MCF7
- Store powder at -20°C for 3 years, or 4°C for 2 years
- Store in solvent at -80°C for 6 months, or -20°C for 1 month
Medchemexpress LLC Vecabrutinib | 1510829-06-7 | 99.76% | 529.92 | 50 MG
Vecabrutinib (SNS-062) is a potent, noncovalent BTK and ITK inhibitor. It demonstrates high specificity and activity, making it suitable for research applications.
- Potent BTK and ITK inhibitor
- Noncovalent binding
- Specific Kd values for BTK (0.3 nM) and ITK (2.2 nM)
- IC50 of 24 nM for ITK